Drug intelligence / Profile preview

MB-07803

Development stage: Phase 2
Lead developer: Ligand Pharmaceuticals
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Administration: Oral

Overview

MB-07803 is a second-generation small molecule gluconeogenesis inhibitor developed for the treatment of type 2 diabetes. It acts as a selective and potent inhibitor of fructose-1,6-bisphosphatase (FBPase), a key regulatory enzyme in the hepatic gluconeogenesis pathway. By inhibiting FBPase, MB-07803 reduces glucose production in the liver independently of insulin levels and body weight. The drug has been investigated up to Phase 2 clinical trials for its ability to lower fasting and postprandial blood glucose in patients with poorly controlled type 2 diabetes.

Other names: 882757-24-6UNII-GG81XF45C2UNII-GG-81XF45C2UNII-GG 81XF45C2

Targets

FBP1 (Fructose-1,6-bisphosphatase 1)FBP2 (Fructose-1,6-bisphosphatase 2)

Beyond the preview

Go deeper on MB-07803.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MB-07803.

Explore the full profile